September 6, 2019 - Contract Pharma
Pharmaceutical development and clinical manufacturing company, Velesco Pharma, is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, MI. The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities. This facility will be supported by Velesco Pharma’s existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the company’s existing manufacturing site in Kalamazoo, MI.
September 5, 2019 - Outsourcing Pharma
The acquisition of Bioclinica’s clinical research site business extends PPD’s trial enrollment business to five continents, 20 countries, and more than 180 research sites.
September 4, 2019 - Fierce Pharma
South Korea’s JW Pharmaceutical has a plan to target emerging markets and has started by snapping up a plant in Vietnam once owned by Valeant. The Seoul-based drugmaker has acquired Euvipharm, getting a 35,000-square-meter manufacturing facility in the deal, Korea Biomedical Review
reports
. Terms of the deal were not disclosed. "This acquisition has enabled us to secure a large-scale plant with advanced technology and modern equipment in the emerging manufacturing powerhouse of Vietnam," JW Pharmaceutical CEO Shin Yeong-seop said in a statement reported by Korea Biomedical. "We will try to spread the JW brand in the global market, starting with Vietnam."
September 2, 2019 - Outsourcing Pharma
Chr. Hansen and Lonza name their joint venture CDMO for live biotherapeutics and ready the launch after receiving antitrust approvals.
